This content is machine translated Myelofibrosis Treatment in transition With the introduction of the Janus kinase (JAK) inhibitor ruxolitinib, therapy for myelofibrosis has changed dramatically in recent years. Nevertheless, further innovation is needed, especially in the second line. Promising…
View Post 4 min This content is machine translated Prognosis of chronic lymphocytic leukemia Coffee grounds and crystal ball of science Valid prognostic and especially predictive markers can play a crucial role in the treatment of cancer. With the development of new therapeutic options for the treatment of chronic lymphocytic leukemia…
View Post 2 min This content is machine translated Iron deficiency Modern treatment management in the lifespan Iron deficiency is a common problem in family practice and can occur throughout a person’s lifespan. The reasons are varied, as are the symptoms that a deficient iron level can…
View Post 6 min This content is machine translated CAR-T Cells Own immune cell as therapy With the rapid development of new therapeutic options in oncology, immunotherapy has a high priority. Thus, CAR T cells are also a promising approach to treat advanced cancers. In particular,…
View Post 11 min This content is machine translated Sideropenia Iron deficiency in the oncological patient Worldwide, iron deficiency is the most common deficiency disease. In Europe, the prevalence is 5-10% and is one of the most common causes of anemia, accounting for about 50%. An…
View Post 2 min This content is machine translated Paroxymal Nocturnal Hemoglobinuria (PNH) Ravulizumab now reimbursable The first approved long-acting complement inhibitor for patients with PNH, ravulizumab, has been approved for nationwide reimbursement by the federal health department. This gives adult PNH patients in Switzerland access…
View Post 5 min This content is machine translated COVID-19 SARS-CoV-2 and the coagulopathy: a Swiss perspective. Within the framework of this year’s Swiss Oncology and Hematology Congress (SOHC), which took place completely virtually for the first time from November 18 to 21, PD Dr. med. Bernhard…
View Post 3 min This content is machine translated Myeloid diseases New trends in the treatment of acute myeloid leukemia Understanding about myeloid diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), is becoming more concrete thanks to intensive research. Recent study results have shown that there is…
View Post 3 min This content is machine translated Sponsored Content Support rational use of blood products in times of COVID-19 – with Patient Blood Management (PBM) PBM is an evidence-based approach that aims to improve clinical outcomes and ensure the safety of the blood supply, while saving money. It is based on the following 3 pillars1,2
View Post 2 min This content is machine translated Schwartz-Bartter syndrome Effectively balancing electrolyte imbalances: focus on osmoregulation Nausea, vomiting, headaches and muscle cramps may also result from water retention. In Schwarzt-Bartter syndrome, this is triggered by ADH accumulation. The cause is usually small cell lung cancer, but…
View Post 3 min This content is machine translated Cancer medicine of the future Car-T cell therapy and its application in practice CAR-T cell technology is considered the latest achievement in cancer medicine. The first approvals in Europe took place in mid-2018 – Switzerland followed at the end of 2018. Currently, the…